

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3

In re application of: Andrews, CW

International Appln. Serial No.: PCT/EP00/08487

Group Art Unit:

International Appln. Filed: 31 August 2000

Examiner:

For: Benzophenones as Inhibitors of Reverse Transcriptase

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☐ Copies of the references are enclosed
☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
☒ A copy of the International Search Report, which issued on International Application No. PCT/EP00/08487 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,

whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No. _____
In accordance with the requirements of 37 CFR 1.97(d):


- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

March 1, 2002


Karen L. Prus
Registration No. 39, 337

GlaxoSmithKline Inc:
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Telephone: (919) 483-2192
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PU3517USW	SERIAL NO. (Intern'l) PCT/EP00/08487
	APPLICANT: Andrews, CW	
	FILING (Intern'l) 31 August 2000	GROUP

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	4 883 815 A	28 NOV 1989	Werner, Aschwenden et al.			
	AB	4 207 234 A	10 JUN 1980	Masashi, Hashimoto et al.			

Continue on page ____

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	BA	WO99 55682 A	4 NOV 1999	PCT			
	BB	1 552 793 A	10 JAN 1969	FR			

Continue on page ____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

	CA	WYATT, PG., et al: "Journal of Medicinal Chemistry, US, American Chemical Society. Washington, JOURNAL OF MEDICINAL CHEMISTRY, US, AMERICAN CHEMISTRY SOCIETY. WASHINGTON, vol. 38, no. 10, 1995, pages 1657-1665 XPOO2084134
	CB	SUGASAWA, T., et al: "1-Azacycloalkyl-1,4-benzodiazepin-2-ones with anxiety-antidepressant actions," J. MED. CHEM. (1985), 28(6), 699-707 XP002159556
	CC	CAPUANO, L., et al: "Darstellung von alpha-'2-alkoxycarbonyl-anilino!-und alpha-'2-Acylanilino!-carbonsaureämidem" JUSTUS LIEBIGS ANN. CHEM. (1968), 712, 73-8 XP002159557
	CD	BRANDL, E.: "Penicillin reactions. 1. Behavior towards penicillinase" SCI. PHARM. (1971), 39(4), 267-92 XP000979965

Continue on page ____

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	